<DOC>
	<DOCNO>NCT02281955</DOCNO>
	<brief_summary>The purpose research study learn effectiveness use lower-intensity radiation chemotherapy treat human papillomavirus ( HPV ) associate low-risk oropharyngeal and/or unknown primary squamous cell carcinoma head neck . The cure rate type cancer estimate high , &gt; 90 % . The standard treatment cancer 7 week radiation 3 high dos cisplatin . Sometimes surgery perform afterwards . This standard regimen cause lot side effect long term complication . This study evaluate whether low dose radiation chemotherapy may provide similar cure rate longer , intensive standard regimen . Patients study receive 1 less week radiation lower weekly dose chemotherapy .</brief_summary>
	<brief_title>De-intensification Radiation Chemotherapy Low-Risk HPV-related Oropharyngeal SCC : Follow-up Study</brief_title>
	<detailed_description>The propose study follow-up study NCT01530997 . In NCT01530997 , patient HPV positive and/or p16 positive low-risk oropharyngeal squamous cell carcinoma ( OPSCC ) receive de-intensified chemoradiotherapy ( CRT ) follow limited surgical evaluation . The primary endpoint NCT01530997 rate pathological complete response ( pCR ) CRT . Power computation perform N=40 base null hypothesis ( H0 ) pCR de-intensified chemoradiotherapy least 87 % , historical rate . The type 1 error calculation 14.2 % . 43 patient enrol 38 evaluable primary endpoint . The observed pCR rate 89 % ( 34/38 ) . Since observe pCR rate excellent NCT01530997 concordance expect rate , propose study mandate post-CRT surgical evaluation . Instead PET/CT 10 16 week post-CRT use determine whether surgical evaluation need .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Oropharyngeal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . ≥ 18 year age ( upper age limit ) 2 . T03 , N0 N2c , M0 squamous cell carcinoma oropharynx 3 . Biopsy proven squamous cell carcinoma HPV and/or p16 positive 4 . ≤ 10 packyears smoke history ≤ 30 packyears smoke history WITH ≥ 5 year abstinence smoke 5 . Radiologic confirmation absence hematogenous metastasis within 12 week prior registration 6 . ECOG Performance Status 01 7 . CBC/differential obtain within 8 week prior registration , adequate bone marrow function define follow : Platelets ≥ 100,000 cells/mm3 ; Hemoglobin ≥ 8.0 g/dl . 8 . Adequate renal hepatic function within 4 week prior registration , define follow : Serum creatinine &lt; 2.0 mg/dl ; Total bilirubin &lt; 2 x institutional ULN ; AST ALT &lt; 3 x institutional ULN . 9 . Negative serum pregnancy test within 2 week prior registration woman childbearing potential 10 . Women childbearing potential male participant sexually active must practice adequate contraception treatment 6 week follow treatment . 11 . Patients must deem able comply treatment plan followup schedule . 12 . Patients must provide study specific informed consent prior study entry 1 . Prior history radiation therapy head neck 2 . Prior history head neck cancer . 3 . Unresectable disease ( e.g . immobile node physical exam , nodal disease radiographgically involve carotid artery , nerve ) 4 . Extensive history use smokeless tobacco product marijuana define daily use &gt; /= 5 year . 5 . Severe , active comorbidity , define follow : Unstable angina and/or congestive heart failure require hospitalization within last 6 month ; Transmural myocardial infarction within last 6 month ; Acute bacterial fungal infection require intravenous antibiotic time registration ; Chronic Obstructive Pulmonary Disease exacerbation respiratory illness require hospitalization preclude study therapy time registration ; Hepatic insufficiency result clinical jaundice and/or coagulation defect ( Note , however , coagulation parameter require entry protocol ) ; Preexisting ≥ grade 2 neuropathy ; Prior organ transplant . 6 . Known HIV positive .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Human Papillomavirus</keyword>
	<keyword>Oropharynx</keyword>
	<keyword>Oropharyngeal Squamous Cell Carcinoma</keyword>
	<keyword>Squamous Cell Carcinoma</keyword>
	<keyword>Radiation Therapy</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>p16</keyword>
</DOC>